Fujirebio Acquires ADx NeuroSciences

Fujirebio Holdings Inc., a subsidiary of H.U. Group Holdings Inc., has acquired ADx NeuroSciences for €40 million. ADx NeuroSciences is now a wholly owned subsidiary of Fujirebio Europe NV.
 
“By welcoming ADx NeuroSciences in the Fujirebio group of companies, Fujirebio will be able to expand its antibody supply business and contract development and manufacturing (CDMO) offerings in the neurodegenerative field to our partners globally,” said Goki Ishikawa, president and CEO of Fujirebio Holdings Inc. “Fujirebio is committed to invest in developing diagnostic kits in the field of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. We are excited to work together with the ADx NeuroSciences team to expand the global neurodegeneration biomarker testing market.”
 
ADx NeuroSciences specializes in generating tailor-made antibodies and developing assays for pharmaceutical and in-vitro diagnostics (IVD) companies. As part of Fujirebio, ADx NeuroSciences will continue to serve its current partners and customers in their diagnostic biomarker development and will continue to expand its portfolio of biomarkers and antibodies to help detect neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Its current pipeline encompasses, next to several phospho-tau specific antibodies for measurement in plasma, biomarkers targeting synaptic degeneration supporting prognosis of these diseases.

“It is a unique opportunity for us to completely integrate the CDMO-based open platform strategy of Fujirebio in this way,” stated Koen Dewaele, CEO of ADx NeuroSciences. “Our partners will benefit from the synergies between our teams and the speed with which we can bring our antibodies and assays to the diagnostics industry and on various platforms.”
 
Fujirebio is a partner for IVD testing solutions and a historical pioneer in neurodegenerative disease diagnostics. The company will combine the know-how and biomarker portfolio of ADx NeuroSciences with both its own solid experience in bringing IVD products to the market and its strategic CDMO partnerships that make unique testing solutions available to the entire diagnostics industry. The acquisition also concentrates considerable additional know-how, expertise, and resources in the Fujirebio Neuro Center of Excellence.
 
Fujirebio is a member of H.U. Group Holdings Inc., whose name represents “Healthcare for you.” Founded in 1950, it has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. With Fujirebio Holdings Inc., located in Tokyo, its subsidiaries are located in Japan, the United States, and Europe. Fujirebio was the first company to develop and market CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, more than 25 years ago. Fujirebio remains the only company with a line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools.
 
ADx NeuroSciences is an R&D driven company specialized in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production, and worldwide commercialization of novel biomarkers. ADx NeuroSciences was founded in 2011 and is now working with the pharmaceutical and diagnostic companies in the United States, Europe, Japan, and China.